The CAG-Z-FUSWT-IRES-EGFP transgenic line 629 [or CAG-Z-FUSWT (629)] has widespread expression of lacZ, that is replaced by expression of wildtype human fused in sarcoma protein (huFUSWT) and EGFP fluorescence following exposure to Cre recombinase. The Cre recombinase-inducible expression of huFUSWT, along with similarly designed transgenic mice harboring the FUSR521G mutant isoform (Stock No. 028021), is useful in studying FUS-linked juvenile amyotrophic lateral sclerosis (ALS; Lou Gehrig's Disease), and the neurodegenerative disorder frontotemporal lobar degeneration (FTLD).
Gang Yu, University of Texas Southwestern Medical Center at Dallas
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Conditional ready (e.g. floxed), Reporter, Inserted expressed sequence, Humanized sequence) |
Nucleo-cytoplasmic shuttling of fused in sarcoma (FUS) occurs by a nuclear localization signal (NLS). The majority of clinical amyotrophic lateral sclerosis (ALS; Lou Gehrig's Disease) and frontotemporal lobar degeneration (FTLD)-associated FUS mutations occur in its C-terminal NLS sequence. Overexpression of wildtype FUS protein can be pathogenic in human patients as well.
CAG-Z-FUSWT-IRES-EGFP transgenic line 629 (simply called CAG-Z-FUSWT (629)) has a floxed-lacZ gene preventing transcription of the downstream bicistronic sequences; a wildtype human fused in sarcoma protein (huFUSWT) and EGFP. Prior to Cre recombinase exposure, lacZ expression is directed to widespread tissues by the CAG promoter, and no expression of huFUSWT or EGFP is observed. When bred to mice that express Cre recombinase, the resulting offspring will have the floxed-lacZ deleted in the cre-expressing tissues; resulting in expression of huFUSWT and EGFP fluorescence in cre-expressing tissues (and continued lacZ expression in other tissues).
Mice hemizygous for the CAG-Z-FUSWT transgene are viable and fertile, born at normal Mendelian ratios, and have no reported phenotypic abnormalities. To date (September 2015), it has not been attempted to make this strain homozygous.
When CAG-Z-FUSWT (629) are bred to C57BL/6-congenic Meox2Cre knock-in animals (Stock No. 003755), germline deletion of floxed-lacZ generates the CAG-FUSWT-IRES-EGFP genotype (simply called CAG-FUSWT). Mice hemizygous for the CAG-FUSWT transgene and heterozygous for Meox2Cre (Tg/+ , +/Cre) have global overexpression of low levels of huFUSWT, resulting in severe deficits in motor function, denervation of the neuromuscular junctions (NMJs), muscle atrophy, neuroinflammation and early lethality (none survive to adulthood; nearly 100% die by postnatal day 30). The level of huFUSWT expression was similar to that of endogenous mouse FUS, resulting in ~2-fold expression levels of total FUS (huFUSWT + mouse FUS) compared to control mice.
In addition, both CAG-FUSR521G (Stock No. 028021 with germline deletion of floxed-lacZ) and CAG-FUSWT transgenic mouse models exhibit no overt motor neuron loss, no apparent ubiquitin-positive aggregation and no mislocalization of FUS in neurons and glia. Transcriptomic analysis of spinal cords revealed that the gene expression pattern is altered in CAG-FUSWT mice, but not significantly altered in CAG-FUSR521G mice. The CAG-FUSWT and CAG-FUSR521G animals display some characteristics of adult ALS. However, the onset of phenotype in the mouse models is earlier, more closely reflecting FUS-linked juvenile ALS.
The CAG-Z-FUSWT-IRES-EGFP transgene was created by Dr. Gang Yu (University of Texas Southwestern Medical Center at Dallas). The transgene was designed with (from 5' to 3') the CMV-IE enhancer/chicken beta-actin hybrid promoter (CAG), a loxP site, the β-galactosidase gene (lacZ) with nuclear translocation signal and triple polyadenylation sequence, a second loxP site, a cDNA sequence encoding the wildtype human fused in sarcoma protein (huFUSWT), an internal ribosome entry site sequence (IRES), the enhanced green fluorescent protein gene (EGFP) and a polyadenylation sequence. The ~13.2 kbp construct was injected into fertilized oocytes from C57BL/6J female mice. Transgenic founders were bred to C57BL/6J animals for germline transmission. CAG-Z-FUSWT-IRES-EGFP founder line 629 (simply called CAG-Z-FUSWT (629)) was identified with single-to-very low copies of the transgene at a single insertion site. CAG-Z-FUSWT (629) was backcrossed to C57BL/6J for at least 13 generations prior to sending to The Jackson Laboratory Repository in 2016. Upon arrival, males were used to cryopreserve sperm. To establish our living colony, an aliquot of the frozen sperm was used to fertilize oocytes from C57BL/6J inbred females (Stock No. 000664).
Of note, the donating investigator reports that, at least once during backcrossing, a heterozygous female was bred to a C57BL/6J inbred male (thus the Y chromosome of the congenic strain is of C57BL/6J origin).
Expressed Gene | GFP, Green Fluorescent Protein, |
---|---|
Expressed Gene | lacZ, beta-galactosidase, E. coli |
Expressed Gene | FUS, fused in sarcoma , human |
Site of Expression | Prior to cre recombination lacZ is widely expressed; the human wildtype fused in sarcoma protein and EGFP are expressed only after cre recombination in cre-expressing tissues. |
Allele Name | transgene insertion 629, Gang Yu |
---|---|
Allele Type | Transgenic (Conditional ready (e.g. floxed), Reporter, Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | |
Gene Symbol and Name | Tg(CAG-lacZ,-FUS,-EGFP)629Gyu, transgene insertion 629, Gang Yu |
Gene Synonym(s) | |
Promoter | CAG, CMV-IE enhancer/chicken beta-actin/rabbit beta-globin hybrid promoter, |
Expressed Gene | GFP, Green Fluorescent Protein, |
Expressed Gene | lacZ, beta-galactosidase, E. coli |
Expressed Gene | FUS, fused in sarcoma , human |
Site of Expression | Prior to cre recombination lacZ is widely expressed; the human wildtype fused in sarcoma protein and EGFP are expressed only after cre recombination in cre-expressing tissues. |
Strain of Origin | C57BL/6J |
Chromosome | UN |
Molecular Note | This transgene consists of the cytomegalovirus immediate early enhancer-chicken beta-actin hybrid (CAG) promoter, a floxed lacZ gene, wild-type human FUS cDNA, IRES, and EGFP coding sequences. Cre-excision of the loxP flanked lacZ DNA sequence allows for translation of FUS and EGFP. Two lines were generated: 629 and 638. Line 629 was chosen as a representative line. |
When maintaining a live colony, transgenic mice may be bred with wildtype (noncarrier) mice from the colony or with C57BL/6J inbred mice (Stock No. 000664). To date (September 2015), it has not been attempted to make this strain homozygous.
When using the CAG-Z-FUSWT-IRES-EGFP transgenic line 629 [CAG-Z-FUSWT (629)] mouse strain in a publication, please cite the originating article(s) and include JAX stock #027898 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non Carrier for Tg(CAG-lacZ,-FUS,-EGFP)629Gyu |
Frozen Mouse Embryo | C57BL/6J-Tg(CAG-lacZ -FUS -EGFP)629Gyu/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | C57BL/6J-Tg(CAG-lacZ -FUS -EGFP)629Gyu/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | C57BL/6J-Tg(CAG-lacZ -FUS -EGFP)629Gyu/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | C57BL/6J-Tg(CAG-lacZ -FUS -EGFP)629Gyu/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.